PDCD1 and neoplasm: Hence, developing new combinational treatment strategies to counter immunoediting mechanisms of tumors such as increasing tumor antigenicity, and depleting Tregs in TME may improve anti-PD1 efficacy in younger patients and therefore needs to be further investigated.